Probing polynuclear platinum biomolecule interactions

四分之一的澳大利亚人患有癌症，50%的癌症患者接受顺铂治疗。BBR3464是一种新型铂抗癌药物，在临床试验中显示出希望，包括对顺铂治疗无反应的癌症的结果。目前正在开发的第二代类似物可能会提供显著的优势。与这些新药发明者的国际合作使澳大利亚的研究处于临床发展的前沿。在设计改进的抗癌药物方面，有可能从新的策略中产生新的知识产权。该项目建立了强大的国际联系，并为澳大利亚博士生提供国际培训。

Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.